EVALUATION OF THE PRIMITIVE AND PROGENITOR FRACTION BY FUNCTIONAL IN VITRO ASSAYS AT THE RNA AND DNA LEVEL REPRESENTS A NOVEL TOOL FOR COMPLEMENTING MOLECULAR MONITORING IN CHRONIC MYELOID LEUKEMIA

BIANCHINI M; MORDOH J; SANCHEZ AVALOS J; PEREZ M; PAVLOVSKY C; FONCUBERTA C; FREITAS F; SANCHEZ MB; RUIZ MS; LARRIPA I; VENTRIGLIA V; GONZALEZ M., GARGALLO P., MOIRAGHI B., LARRIPA I; CUSTIDIANO M

oncotarget

Impact Journal

Lugar: New York; Año: 2018 vol. 9 p. 20255 - 20264

Quantification of BCR-ABL1 mRNA levels in peripheral blood of chronic myeloidleukemia patients is a strong indicator of response to tyrosine-kinase inhibitors (TKI)treatment. However, additional prognostic markers are needed in order to better classify patients. The hypothesis of leukemic stem cells (LSCs) heterogeneity and persistence, suggests that their functional evaluation could be of clinical interest. In this work, we assessed the primitive and progenitor fractions in patients at diagnosis and during TKI treatment using functional in vitro assays, defining a ?functional leukemic burden? (FLB). We observed that the FLB was reduced in vivo in both fractions upon treatment. However, different FLB levels were observed among patients according to their response to treatment, suggesting that quantification of the FLB could complement early molecular monitoring. Given that FLB assessment is limited by BCR-ABL1 mRNA expression levels, we developed a novel detection method of primitive cells at the DNA level, using patient-specific primers and direct nested PCR in colonies obtained from functional in vitro assays. We believe that this methodcould be useful in the context of discontinuation trials, given that it is unknown whether the persistent leukemic clone represents LSCs, able to resume the leukemia upon TKI removal.